Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Libtayo
Pharma
FDA approves Regeneron's Libtayo for adjuvant use in CSCC
The FDA has approved Libtayo as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma.
Kevin Dunleavy
Oct 9, 2025 11:00am
Regeneron lays out bright future for newest blockbuster Libtayo
Feb 4, 2025 11:28am
Regeneron touts Eylea HD launch, warns of potential approval delay
Aug 1, 2024 11:15am
Docs ask pharma for more NSCLC drugs, resources and research
Jan 25, 2024 6:30am
Regeneron passes some European Libtayo rights to Medison Pharma
Jan 8, 2024 3:47pm
Regeneron's Libtayo delivers lung cancer win with BMS' Yervoy
Dec 1, 2022 12:25pm
